25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Atopic dermatitis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life of affected individuals as well as their families. Although the pathogenesis of the disorder is not completely understood, it appears to result from the complex interplay between defects in skin barrier function, environmental and infectious agents, and immune dysregulation. There are no diagnostic tests for AD; therefore, the diagnosis is based on specific clinical criteria that take into account the patient’s history and clinical manifestations. Successful management of the disorder requires a multifaceted approach that involves education, optimal skin care practices, anti-inflammatory treatment with topical corticosteroids and/or topical calcineurin inhibitors, the management of pruritus, and the treatment of skin infections. Systemic immunosuppressive agents may also be used, but are generally reserved for severe flare-ups or more difficult-to-control disease. Topical corticosteroids are the first-line pharmacologic treatments for AD, and evidence suggests that these agents may also be beneficial for the prophylaxis of disease flare-ups. Although the prognosis for patients with AD is generally favourable, those patients with severe, widespread disease and concomitant atopic conditions, such as asthma and allergic rhinitis, are likely to experience poorer outcomes.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Atopic dermatitis and the atopic march.

          J. Spergel (2003)
          Atopic dermatitis (AD), one of the most common skin disorders seen in infants and children, usually has its onset during the first 6 months of life. The prevalence of AD is similar in the United States, Europe, and Japan and is increasing, similar to that of other atopic disorders, particularly asthma. AD has been classified into 3 sequential phases: infantile, childhood, and adult, each with characteristic physical findings. AD has a tremendously negative effect on the quality of life of patients as well as family, most commonly disturbing sleep. The condition also creates a great financial burden for both the family and society. The cutaneous manifestations of atopy often represent the beginning of the atopic march. On the basis of several longitudinal studies, approximately half of AD patients will develop asthma, particularly with severe AD, and two thirds will develop allergic rhinitis. Epicutaneous sensitization has been thought to be responsible, with subsequent migration of sensitized T cells into the nose and airways, causing upper and lower airway disease. Animal models and human observation concur with this theory. Preliminary prevention studies with oral antihistamines provide evidence that early intervention might slow the atopic march.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Allergen immunotherapy: a practice parameter third update.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation.

              In order to qualify as a case of atopic dermatitis, we propose that an individual must have an itchy skin condition plus three or more of the following: history of flexural involvement, a history of asthma/hay fever, a history of a generalized dry skin, onset of rash under the age of 2 years, or visible flexural dermatitis. When tested in an independent sample of 200 consecutive dermatology outpatients of all ages, this arrangement of the diagnostic criteria achieved 69% sensitivity and 96% specificity when validated against physician's diagnosis. Based on the findings of this first exercise, minor modifications in the wording of the criteria were undertaken, and these were tested on a sample of 114 consecutive children attending out-patient paediatric dermatology clinics. Overall discrimination improved, with a sensitivity of 85% and specificity of 96%. The simplified criteria are easy to use, take under 2 min per patient to ascertain, and do not require subjects to undress. These two independent validation studies suggest that the newly proposed criteria for atopic dermatitis perform reasonably well in hospital out-patient patients. Further validation in community settings and in developing countries is needed.
                Bookmark

                Author and article information

                Contributors
                sandy.kapur@gmail.com
                Journal
                Allergy Asthma Clin Immunol
                Allergy Asthma Clin Immunol
                Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
                BioMed Central (London )
                1710-1484
                1710-1492
                12 September 2018
                12 September 2018
                2018
                : 14
                Issue : Suppl 2 Issue sponsor : Publication of this supplement has been supported by AstraZeneca, Boehringer Ingelheim, CSL Behring Canada Inc., MEDA Pharmaceuticals Ltd., Merck Canada Inc., Pfizer Canada Inc., Shire Pharma Canada ULC, Stallergenes Greer Canada, Takeda Canada, Teva Canada Innovation, Aralez Tribute and Pediapharm. The articles have undergone the journal's standard peer review process for supplements. HK is the vice-president of the CSACI, has been on advisory boards and speaking bureaus for the following: Astrazeneca, CSL Behring, Shire, Novartis, Pediapharm, Aralez, Mylan, Sanofi, and does not hold any stocks and is not applying for or holds patents. RW is the past president of the Canadian Society of Allergy & Clinical Immunology, Editor-in-Chief of Allergy, Asthma & Clinical Immunology and has received consulting fees and honoraria from Nycomed, CSL Behring, Talecris, Grifols, Novartis and Shire. WW is a co-chief editor of Allergy, Asthma & Clinical Immunology and has received honoraria for continuing education from Pfizer Canada. All Supplement Editors confirm they were not involved in the review process of papers that they are listed as authors.
                : 52
                Affiliations
                [1 ]ISNI 0000 0004 1936 8200, GRID grid.55602.34, IWK Health Centre, Division of Allergy, Department of Pediatrics, , Dalhousie University, ; Halifax, NS Canada
                [2 ]GRID grid.17089.37, Department of Pediatrics, , University of Alberta, ; Edmonton, AB Canada
                Article
                281
                10.1186/s13223-018-0281-6
                6157251
                30275844
                b4ab1108-1fcb-457f-af38-b4318fcc9472
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                Categories
                Review
                Custom metadata
                © The Author(s) 2018

                Immunology
                atopic dermatitis,diagnosis and management,emollients,skin care practices,topical corticosteroids,topical calcineurin inhibitors

                Comments

                Comment on this article